Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin/Metformin FDC PK/PD Study
NCT03355014Phase 1Completed
- Sponsor
- LG Chem
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Dec 2017; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03355014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355014.